Financial Summary

Aptevo Therapeutics Inc. (APVO)

Healthcare

Income Statement

Year	2013	2014	2015	2016	2017	2018
Earnings Per Share Basic	-	-	-2.93	-5.55	0.33	-2.39
Net Profit Margin	-313.75	-1.12	-1.77	-11.26	0.48	-2.33
Earnings Per Share Diluted	-	-	-2.93	-5.55	0.33	-2.39
Revenue	0.17	45.63	33.60	9.98	14.66	23.07
Weighted Average Shares Outstanding	-	-	20.21	20.25	21.43	22.69
Gross Profit	0.17	29.38	16.67	-2.48	9.65	11.85
Weighted Average Shares Outstanding (Diluted)	-	-	20.23	20.24	21.34	22.50
Sales, General and Administrative Expense	15.45	34.28	43.04	36.16	34.58	28.13
Dividend per Share	-	-	-	-	-	-
Operating Income	-53.34	-51.71	-61.10	-138.77	-53.95	-51.66
Gross Margin	1.00	0.64	0.50	-0.25	0.66	0.51
Earnings before Tax	-53.34	-51.71	-61.34	-132.11	-16.33	-53.69
EBITDA Margin	-309.83	-1.09	-1.74	-12.89	-0.90	-2.22
Net Income	-53.34	-51.12	-59.32	-112.42	6.97	-53.69
EBIT Margin	-313.75	-1.13	-1.83	-13.23	-1.11	-2.33
Net Income - Discounted ops	-	-	-	-	-	-
Profit Margin	-313.75	-1.12	-1.76	-11.26	0.48	-2.33
Preferred Dividends	-	-	-	-	-	-
Free Cash Flow margin	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
R&D Expenses	38.07	46.59	34.73	29.12	29.02	35.38
Interest Expense	-	-	-	-	-	-
Earnings Before Tax Margin	-313.75	-1.13	-1.83	-13.23	-1.11	-2.33
Consolidated Income	-53.34	-51.12	-59.32	-112.42	6.97	-53.69
EBIT	-53.34	-51.71	-61.34	-132.11	-16.33	-53.69
EBITDA	-52.67	-49.69	-58.43	-128.75	-13.20	-51.30
Income Tax Expense	-	-0.60	-2.02	-19.69	-23.30	-
Operating Expenses	53.51	81.09	77.77	136.29	63.60	63.52
Cost of Revenue	-	16.25	16.93	12.47	5.01	11.21
Net Income Com	-53.34	-51.12	-59.32	-112.42	6.97	-53.69
Net Income - Non-Controlling int	-	-	-	-	-	-

Balance Sheet Statement

Year	2014	2015	2016	2017	2018
Total current liabilities	19.84	19.94	19.54	18.51	17.61
Other Liabilities	8.36	9.86	9.03	7.83	5.94
Long-term debt	-	-	18.38	15.73	19.28
Cash and cash equivalents	3.59	4.64	10.08	7.50	38.08
Total debt	-	-	18.38	19.06	19.28
Cash and short-term investments	3.59	4.64	54.92	81.18	38.08
Deferred revenue	4.54	7.16	3.71	-	-
Inventories	17.63	20.32	0.46	1.03	1.78
Tax Liabilities	1.87	15.82	-	-	-
Goodwill and Intangible Assets	25.12	46.65	6.91	6.08	5.25
Deposit Liabilities	-	-	-	-	-
Tax assets	1.31	1.38	-	-	-
Total non-current liabilities	5.53	19.21	21.75	16.46	19.48
Total current assets	41.55	35.13	71.41	95.08	48.69
Total liabilities	25.36	39.15	41.29	34.97	37.09
Payables	11.47	10.08	10.52	7.35	11.67
Other comprehensive income	-	-	-0.03	-0.10	-
Short-term investments	-	-	44.85	73.69	-
Retained earnings (deficit)	-172.67	-231.99	-80.69	-73.72	-127.41
Property, Plant & Equipment Net	3.20	4.18	5.91	5.84	5.20
Total non-current assets	78.42	92.63	20.44	21.92	18.80
Other Assets	6.51	3.72	15.72	10.73	3.60
Net Debt	-3.59	-4.64	-36.54	-62.12	-18.80
Investments	-	-	44.85	83.69	-
Total shareholders equity	94.61	88.62	50.57	82.03	30.41
Total assets	119.97	127.77	91.86	117.01	67.49
Long-term investments	-	-	-	10.00	-
Receivables	13.82	6.46	0.31	2.14	5.22
Short-term debt	-	-	-	3.33	-

Cash Flow Statement

Year	2013	2014	2015	2016	2017	2018
Insurance (repayment) of debt	-	-	-	-	-	-
Net Cash/Marketcap	0.00	0.00	0.00	0.00	0.00	0.00
Insurance (buybacks) of shares	-	-	-	-	-	-
Depreciation & Amortization	0.67	2.02	2.91	3.36	3.13	2.39
Dividend payments	-	-	-	-	-	-
Operating Cash Flow	-51.39	-47.01	-48.76	-36.86	-41.57	-51.42
Acquisitions and disposals	-	-47.81	-	-	59.76	0.07
Free Cash Flow	-52.41	-48.00	-50.29	-39.37	-42.98	-52.40
Net cash flow / Change in cash	-	3.59	1.04	5.04	7.42	20.59
Effect of forex changes on cash	-	-	-	-	-	-
Financing Cash Flow	52.41	99.40	51.33	89.30	19.53	-0.79
Investment purchases and sales	-	-	-	-44.88	-28.90	73.71
Capital Expenditure	-1.02	-0.99	-1.53	-2.51	-1.40	-0.98
Stock-based compensation	0.95	1.07	1.11	3.81	4.88	2.14
Investing Cash Flow	-	-	-	-	-	-

Aptevo Therapeutics Inc. (APVO)

0.6

0 (-0.78%)

---

About

---

CEO

Marvin L. White

Sector

Healthcare

Industry

Biotechnology

Website

http://www.aptevotherapeutics.com

Exchange

Nasdaq Global Select

Description

Aptevo Therapeutics Inc is a biosciences company. The Company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.

Market Information

---

Stock Value >

Financial Information

---

Financial Summary >

Financial Statements >

Ratios Analysis >

Dupont Analysis >

Free Cash Flow >

Operating Data >

Balance Sheet Data >

Financial Modelling

---

Discounted Cash Flow Model >

Discounted Cash Flow Model Levered >

Free Cash Flow Build Up >

Terminal Value >

Intrinsic Value >

Weighted Average Cost of Capital >

View APVO stock quote and the basic stock chart on Financial Modeling Prep traded on to be able to build its financial statements. You can find all financial models and valuation techniques that is used in corporate finance to get intrinsic valuation. Change the date range, chart type and compare it against other companies for decision making when it comes to hold, buy or sell a particular stock.